|
Ann L. Wang joined HGS as Director of Clinical Operations in December 2000. She was promoted to Vice President Clinical Operations in December 2003. Prior to HGS Ms. Wang was Director of Clinical Operations for Pharmaceutical Research Associates International (PRA) a contract research organization where she was responsible for directing delivery of clinical trials services to PRA clients. From 1988-1998 Ms. Wang advanced through a series of clinical operations positions of increasing responsibility at Centocor Inc. ultimately serving as Associate Director Clinical Operations and Administration. While at Centocor she led implementation of the program leading to worldwide approval of the recombinant antiplatelet drug ReoPro. Ms. Wang began her career in as a bench scientist first at the Lombardi Cancer Research Center of Georgetown University and then at SmithKline & French where she was responsible for establishing a Molecular Oncology laboratory. Ms. Wang earned her B.A. in Organismal Biology at The Johns Hopkins University and did postgraduate work at Georgetown University in physiology. | 